ProImmune, a leader in services for understanding immune responses, today announced the introduction of MutaMap™, a new high-throughput assay service for understanding the impact of point mutations on protein therapeutic activity, including monoclonal antibodies. MutaMap provides a high-throughput service, with high-quality output data, to help decide which individual point mutations to pursue and enable better protein engineering decisions to be made, prior to committing a drug candidate to a clinical program.
MutaMap is an in vitro assay system that explores the effect of deliberate point mutations on protein activity by substituting each of the 19 possible amino acid alternatives in each position in a protein sequence, one by one. Each position of a protein of interest is altered by site-directed mutagenesis, expressed and changes in affinity or activity measured using cell-free in vitro translation of proteins and solution titration assays. These methods avoid the use of surrogate measurements for affinity ...
